Gapping up
News:
News:
- HVII +17.9% (Closed the ONE Nuclear Energy business combination, with the renamed company's shares set to begin Nasdaq trading.)
- KYTX +8.3% (Reported positive one-year miv-cel data in stiff person syndrome; rolling BLA completion remains on track for Q4 2026.)
- ARCT +6.9% (Reported interim Phase 2 ARCT-810 safety and biomarker improvements and unveiled the higher-expression LUNAR 2.0 platform.)
- MSLE +5.9% (Receives FDA clearance to begin Phase II forazapadin study in FSHD, backed by up to $5 million financing.)
- FRVO +5.4% (Achieved first power at Cape Station, synchronizing its Utah enhanced geothermal project to the grid and exporting electricity.)
- MESO +5.1% (Received FDA approval to use a new potency assay for commercial Ryoncil lot release and stability monitoring.)
- GRAL +4.1% (FDA advisory panel backed Galleri's benefit-risk profile for cancer screening, with a final approval decision expected within months.)
- DLB +4.0% (Expanded its Meta partnership, adding Dolby Atmos and Vision support across AI glasses, Instagram and next-generation VR.)
- NMRK +3.5% (Secured an engagement to advise SSOF on Nevada powered-land development strategy and administer a competitive partner RFP.)
- CTKB +3.0% (Launched a U.S. cloud-based flow cytometry analysis tool and premium subscription tier.)
- BZUN +2.7% (Authorized a $10 million share repurchase program over the next 12 months.)
- RGNX +2.5% (Settled patent litigation with Sarepta, securing a $39 million payment within 10 days.)
- KNF +2.5% (Starboard criticized Knife River's underperformance and urged its board to consider a sale if operational standards remain unmet.)
- KBR +1.8% (Appointed Michael LaRouche CEO-designate of Trinzic ahead of the planned January 2027 Mission Technology Solutions spin-off.)